(NASDAQ: TCRT) Alaunos Therapeutics's forecast annual revenue growth rate of 14,201,400% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,700.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 1,464.38%.
Alaunos Therapeutics's revenue in 2025 is $4,000.On average, 4 Wall Street analysts forecast TCRT's revenue for 2025 to be $1,267,812,782, with the lowest TCRT revenue forecast at $1,218,109,950, and the highest TCRT revenue forecast at $1,305,106,644.
In 2026, TCRT is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.